Gynecologic Cancer

Top Story

FDA grants priority review to Lynparza for metastatic BRCA-related breast cancer

October 18, 2017

The FDA granted priority review to olaparib for the treatment of patients with germline BRCA-mutated, HER-2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic settings.

Olaparib (Lynparza; AstraZeneca, Merck) is a PARP inhibitor approved for use in women with BRCA-related ovarian cancer.

AACR: Advances in cancer research, medical funding allow for ‘phenomenal’ progress

October 17, 2017
Oncology leaders who participated in an American Association for Cancer Research webinar this afternoon highlighted several advances in cancer research and emphasized…
In the Journals Plus

Cadmium exposure may increase risk for endometrial cancer

October 13, 2017
Women with high levels of cadmium exposure appeared to have increased risk for endometrial cancer, according to a population-based, case-control study published in PLOS

NIH collaboration aims to identify, validate immunotherapy biomarkers

October 13, 2017
NIH launched the Partnership for Accelerating Cancer Therapies, a 5-year public-private research collaboration. The $215 million effort is part of the national cancer…
More Headlines »
CME

Diagnostic and Therapeutic Challenges in Von Willebrand Disease

This activity is supported by an educational grant from Shire.

With the significant variability in the subtypes and clinical manifestations of von Willebrand disease (VWD), diagnosis…
More »
Video

Baseball great Mike Schmidt became ‘concerned about dying’ after melanoma diagnosis

September 25, 2017
More »
Resource Centers
European Society for Medical Oncology Congress

European Society for Medical Oncology Congress

CME

Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

This activity is supported by an educational grant from Merck & Co, Inc.

Advances in immunology and the advent of immune checkpoint blockade inhibition for advanced bladder cancer are poised…
More »
Advertisement
Advertisement